Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04669158 · ClinicalTrials.gov registry record · Phase 1

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

A Phase 1 study, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
53
Enrollment target

NCT04669158: Completed Phase 1 study, sponsored by Stanford University.

NCT04669158 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04669158, a Phase 1 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
53 participants
Enrollment target

Study Summary

This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.

Interventions

  • DRUG Placebo
  • DRUG Idebenone

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2021-07-30
Est. Completion 2023-07-05
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT04669158

The ClinicalTrials.gov registry entry for NCT04669158 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04669158 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04669158 about?

NCT04669158 is a clinical study titled "Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis". This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.

What is the current status of trial NCT04669158?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2021-07-30. Estimated completion is 2023-07-05.

What interventions are being tested in trial NCT04669158?

The interventions under investigation include: Placebo (DRUG), Idebenone (DRUG).

Who is sponsoring clinical trial NCT04669158?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.